Single-agent chemotherapy of brain tumors. A five-year review.

  title={Single-agent chemotherapy of brain tumors. A five-year review.},
  author={Charles Bo Wilson and Philip H. Gutin and E B Boldrey and D Drafts and V. A. Levin and K J Enot},
  journal={Archives of neurology},
  volume={33 11},
Identification of effective single chemotherapeutic agents for brain tumors must precede the rational use of multiple drug combinations. In phase 2 trials beginning in 1968, 158 patients with intrinsic brain tumors (mostly recurrent malignant astrocytomas) were considered evaluable. The larger trials with more effective drugs produced these results: carmustine (BCNU) response rate, 47%, with median duration of nine months; lomustine (CCNU), 44%, with median duration of six months; procarbazine… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 28 extracted citations

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing

Clinical pharmacology : advances and applications • 2013
View 5 Excerpts
Highly Influenced

The history of ependymoma management

Child's Nervous System • 2009
View 1 Excerpt

In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006

Similar Papers

Loading similar papers…